Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12588925 | 0.90 | OPRM1 (0.49) | OPRM1GAAOPRD1OPRK1 | |
| SCHEMBL12646375 | 0.88 | GAA (0.52) | OPRM1GAAOPRD1OPRK1 | |
| SCHEMBL10222586 | 0.84 | OPRM1 (0.55) | OPRM1GAAOPRD1OPRK1 | |
| SCHEMBL12588898 | 0.80 | OPRM1 (0.53) | OPRM1GAAOPRD1OPRK1 | |
| SCHEMBL10066077 | 0.79 | GAA (0.54) | OPRM1GAAOPRD1OPRK1 | |
| SCHEMBL10391150 | 0.77 | GAA (0.52) | OPRM1GAAOPRD1OPRK1 | |
| SCHEMBL10222583 | 0.77 | OPRM1 (0.33) | OPRM1GAAOPRD1OPRK1 | |
| SCHEMBL12646332 | 0.77 | OPRM1 (0.51) | OPRM1GAAOPRD1OPRK1 | |
| SCHEMBL12646269 | 0.77 | GAA (0.51) | OPRM1GAAOPRD1OPRK1 | |
| SCHEMBL12588922 | 0.76 | OPRM1 (0.58) | OPRM1GAAOPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142502-B2 | (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof | MALLINCKRODT LLC (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172488-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC | 2020-06-04 | — | — | US | disclosed |
| US-10363251-B2 | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof | MALLINCKRODT LLC (US) | 2019-07-30 | — | — | US | disclosed |
| EP-2453895-B1 | (+) - MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9562014-B2 | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof | MALLINCKRODT LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170029432-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT ENTERPRISES LLC | 2017-02-02 | — | — | US | disclosed |
| US-20150335638-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | STRATATECH CORPORATION | 2015-11-26 | — | — | US | disclosed |
| US-20110136845-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | MALLINCKRODT INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110015219-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | MALLINCKRODT INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029432-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | TLR9, TLR3, TLR7 | OPRM1 5/4885GAA 1100/4885OPRD1 13/4885 |
| US-20110136845-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | TLR9, TLR3, TLR7 | OPRM1 5/4885GAA 1100/4885OPRD1 13/4885 |
| US-10363251-B2 | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof | TLR9, TLR3, TLR7 | OPRM1 30/4885GAA 1006/4885OPRD1 141/4885 |
| US-11142502-B2 | (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof | TLR9, TLR3, TLR7 | OPRM1 5/4885GAA 1100/4885OPRD1 13/4885 |
| US-20200172488-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | TLR9, TLR3, TLR7 | OPRM1 5/4885GAA 1100/4885OPRD1 13/4885 |
| US-20150335638-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | TLR9, TLR3, TLR7 | OPRM1 30/4885GAA 1006/4885OPRD1 141/4885 |
| US-20110015219-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | TLR9, TLR3, TLR1 | OPRM1 17/4885GAA 2289/4885OPRD1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.